Sangamo Therapeutics, Inc. Common Stock (SGMO) Stock Price

SGMOStock

$0.14−89.24%52W

Market Cap$57.96M

P/E—

PEG Ratio—

Div yield—

Beta1.74

SGMO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-65.54%

Price vs S&P 500 (4W)-10.66%

VGM Score43.05

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)9.35x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-29.17%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)-77.65%

Net Profit Margin (TTM)-356.89%

EPS (TTM)$-0.38

10-Day Avg Trading Volume2.15M

EPS Excl Extra (TTM)$-0.38

Revenue Growth (5Y)-19.66%

EPS (Annual)$-0.44

ROI (Annual)-430.13%

Net Profit Margin (5Y Avg)-192.08%

Cash / Share (Quarterly)$0.07

Revenue Growth QoQ (YoY)-77.60%

ROA (Last FY)-205.76%

Revenue Growth TTM (YoY)-45.80%

EBITD / Share (TTM)$-0.37

ROE (5Y Avg)-175.64%

Operating Margin (TTM)-357.55%

Cash Flow / Share (Annual)$-0.28

P/B Ratio9.29x

P/B Ratio (Quarterly)32.54x

Net Income / Employee (Annual)$-865,700

EV / Revenue (TTM)0.88x

Net Interest Coverage (TTM)-222.00x

ROA (TTM)-161.26%

EPS Incl Extra (Annual)$-0.44

Current Ratio (Annual)0.84x

Quick Ratio (Quarterly)0.64x

3-Month Avg Trading Volume3.94M

52-Week Price Return-89.24%

Revenue / Employee (TTM)$243,400

Tangible BV / Share (Quarterly)$0.11

P/S Ratio (Annual)1.47x

Asset Turnover (Annual)0.66x

52-Week High$0.72

Operating Margin (5Y Avg)-197.67%

EPS Excl Extra (Annual)$-0.44

CapEx CAGR (5Y)-63.00%

Tangible BV CAGR (5Y)-43.03%

26-Week Price Return-53.05%

Quick Ratio (Annual)0.74x

13-Week Price Return113.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.70x

Enterprise Value$30.41M

Revenue / Share Growth (5Y)-30.64%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-50.84%

Revenue / Employee (Annual)$278,500

Pretax Margin (Annual)-312.25%

Cash / Share (Annual)$0.06

3-Month Return Std Dev134.05%

Net Income / Employee (TTM)$-868,500

ROE (Last FY)-430.13%

EPS Basic Excl Extra (Annual)$-0.44

P/FCF (TTM)4.98x

Receivables Turnover (TTM)55.78x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.38

Receivables Turnover (Annual)88.19x

ROI (TTM)-813.95%

P/S Ratio (TTM)1.68x

Pretax Margin (5Y Avg)-192.86%

Revenue / Share (Annual)$0.14

Tangible BV / Share (Annual)$0.11

Price vs S&P 500 (52W)-90.49%

Year-to-Date Return-66.45%

5-Day Price Return-4.67%

EPS Normalized (Annual)$-0.44

ROA (5Y Avg)-103.40%

Net Profit Margin (Annual)-310.81%

Month-to-Date Return-3.43%

Cash Flow / Share (TTM)$-1.36

EBITD / Share (Annual)$-0.42

Operating Margin (Annual)-306.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-175.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.38

P/TBV (Quarterly)9.35x

P/B Ratio (Annual)9.35x

Pretax Margin (TTM)-358.88%

Book Value / Share (Annual)$0.11

Price vs S&P 500 (13W)110.68%

Beta1.74x

P/FCF (Annual)0.37x

Revenue / Share (TTM)$0.09

ROE (TTM)-813.95%

52-Week Low$0.03

vGradeB

gGradeF

mGradeC

vgmGradeC

SGMO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 14, 2026	-$0.07	-$0.08	-14.29%(-$0.01)
Q4 2025	Mar 30, 2026	-$0.05	-$0.07	-54.70%(-$0.03)
Q3 2025	Nov 6, 2025	-$0.10	-$0.11	-6.46%(-$0.01)
Q2 2025	Aug 7, 2025	-$0.13	-$0.08	+36.00%(+$0.05)

SGMO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SGMOSangamo Therapeutics, Inc. Common Stock	B	F	C	1.7x	-45.8%	—	—	$0.14
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Sangamo Therapeutics, Inc. Common Stock

Sangamo Therapeutics is a genomic medicine company developing gene-based therapies for serious genetic and neurological diseases. Its pipeline includes programs in neurology (chronic neuropathic pain, prion disease, ALS, FTD, Huntington's disease), hematology (hemophilia A), and other indications including Fabry disease and multiple sclerosis, with several programs advanced through partnerships.